Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -65.46% | -557.08% | -682.77% | 46.49% | -84.83% |
| Total Depreciation and Amortization | -2.46% | 11.02% | 8.94% | 20.48% | 17.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.48% | 994.97% | -66.47% | -42.36% | -7.82% |
| Change in Net Operating Assets | 197.06% | 36.82% | -209.33% | -109.68% | 64.00% |
| Cash from Operations | -2,088.80% | -138.61% | -129.48% | -98.26% | -103.16% |
| Capital Expenditure | -155.36% | -11.97% | 35.01% | -49.76% | -49.74% |
| Sale of Property, Plant, and Equipment | -81.82% | 2.09% | -95.24% | -69.74% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -342.67% | 98.34% | 232.10% | -595.47% | 297.96% |
| Cash from Investing | -386.49% | 97.10% | 219.68% | -911.72% | 264.27% |
| Total Debt Issued | 634.49% | -49.16% | 41,720.00% | 46,266.67% | -50.50% |
| Total Debt Repaid | 42.75% | -2,015.11% | -3.57% | -2.16% | -992.09% |
| Issuance of Common Stock | -46.15% | -36.41% | -6.80% | -37.69% | -92.29% |
| Repurchase of Common Stock | 97.78% | 96.71% | 98.83% | -64.71% | -7,167.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 134.48% | 66.32% | 116.06% | -52.07% | -815.75% |
| Foreign Exchange rate Adjustments | 152.61% | -6.98% | 189.71% | -140.72% | -172.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -630.93% | 96.18% | 214.06% | -325.92% | -328.06% |